A. Solms

发表

Exposure–response relationship of regorafenib efficacy in patients with hepatocellular carcinoma

B. Ploeger, J. Bruix, G. Meinhardt, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach

A. Iorio, E. Berntorp, A. Solms, 2019, Clinical Pharmacokinetics.

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

M. Karlsson, E. Nielsen, S. Jönsson, 2019, Haematologica.

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation

Manesh R Patel, K. Fox, S. Berkowitz, 2020, Journal of Thrombosis and Thrombolysis.

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

S. Berkowitz, S. Willmann, W. Mueck, 2019, CPT: pharmacometrics & systems pharmacology.

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin

W. Huisinga, C. Kloft, M. Zeitlinger, 2021, Pharmaceutical Research.

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

A. Iorio, M. Mancuso, T. Lissitchkov, 2020, Annals of Hematology.

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

A. Iorio, M. Mancuso, T. Lissitchkov, 2019, Annals of Hematology.

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism

K. Fox, S. Berkowitz, J. Weitz, 2020, Journal of Thrombosis and Thrombolysis.

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism

K. Fox, S. Berkowitz, J. Weitz, 2020, Journal of Thrombosis and Thrombolysis.

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

S. Bhanot, R. Yu, R. Geary, 2021, CPT: pharmacometrics & systems pharmacology.

Optimising prophylaxis in haemophilia A: The ups and downs of treatment.

C. Hermans, M. Mancuso, E. Berntorp, 2021, Blood reviews.

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

D. Gultyaev, J. O’Hara, A. Solms, 2022, BMC Medical Research Methodology.

Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII

M. Karlsson, E. Nielsen, S. Jönsson, 2019, CPT: pharmacometrics & systems pharmacology.

Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A

Y. Katterle, T. Lissitchkov, A. Solms, 2016, Clinical Pharmacokinetics.

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study

Michael Wang, C. Santoro, S. von Mackensen, 2020, European journal of haematology.

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection

G. Kenet, S. Lalezari, A. Solms, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

TDMx: a novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine.

S. Wicha, C. Kloft, A. Solms, 2015, International journal of antimicrobial agents.

Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations

S. Willmann, W. Mueck, S. Schmidt, 2018, CPT: pharmacometrics & systems pharmacology.

Modeling Interindividual Variability in Physiologically Based Pharmacokinetics and Its Link to Mechanistic Covariate Modeling

W. Huisinga, W Huisinga, A Solms, 2012, CPT: pharmacometrics & systems pharmacology.

Meta‐analysis for diagnostic accuracy studies: a new statistical model using beta‐binomial distributions and bivariate copulas

Oliver Kuss, Annika Hoyer, O. Kuss, 2014, Statistics in medicine.

Exposure-response (ER) relationship of regorafenib (REG) in patients with hepatocellular carcinoma (HCC).

B. Ploeger, J. Bruix, G. Meinhardt, 2017 .

Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.

J. Haerting, D. Burkhoff, H. Thiele, 2011, The Cochrane database of systematic reviews.

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis

T. Steger-Hartmann, A. Rottmann, S. Reif, 2023, Drugs in R&D.

Monoclonal Antibody Disposition beyond Target Binding: Impact of FcRn on Clearance and Derivation of Mechanistic Compartment Models

W. Huisinga, A. Solms, S. Pilari, 2012 .

Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective

T. Rieger, Yaming Hang, A. Solms, 2023, Clinical pharmacology and therapeutics.

Evaluation of covariate effects in item response theory models

Gustaf J. Wellhagen, M. Kjellsson, A. Solms, 2024, CPT: pharmacometrics & systems pharmacology.

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches

A. Solms, C. Becker, D. Garmann, 2023, Clinical Pharmacokinetics.

A concentration-QTc analysis of vericiguat

A. Solms, M. Meyer, C. Becker, 2021, European Heart Journal.

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

P. Holme, G. Kenet, S. Lalezari, 2024, Drugs in R&D.